# US 2009/0221699 A1 · Fab I Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221699 A1
- Document ID: US20090221699A1
- Status: Published application
- Kind: A1
- Application number: 11/767,967
- Filed: 2007-06-25
- Published: 2009-09-03
- Earliest claimed: 2001-04-06
- Assignees: Affinium Pharmaceuticals, Inc.
- Inventors: Walter J. Burgess; Dalia Jakas; William F. Huffman; William H. Miller; Kenneth A. Newlander; Mark A. Seefeld; Irene N. Uzinskas
- Web page: https://patentgrep.com/patent/US20090221699A1

## CPC

- C07D 213/73: Unsubstituted amino or imino radicals
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/381: having five-membered rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/47: Quinolines; Isoquinolines
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4

A method of treating a bacterial infection in a subject in need thereof, comprising administering a therapeutically effective amount of the compound, (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, or pharmaceutically acceptable salts thereof, to said subject.

### Claim 5

The compound (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 5)

A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.

### Claim 7

A composition comprising a pharmaceutically acceptable salt of (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide and a pharmaceutically acceptable carrier.
